An official website of the United States Government -

Prescription Drugs

Outpatient prescription drug coverage is an optional benefit that all state Medicaid programs have elected to provide. In fiscal year (FY) 2017, Medicaid spent approximately $64.0 billion on outpatient prescription drugs and collected $34.9 billion in rebates, resulting in net drug spending of $29.1 billion, or about 5.1 percent of total Medicaid benefit spending that year. Although prescription drug spending growth has slowed over the past few years, controlling prescription drug spending remains a focus for policymakers because prescription drugs are expected to experience one of the largest growth rates in average annual spending among major health care goods and services over the next 10 years, due in part to the anticipated growth of new high-cost treatments (Sisko et al. 2019).

Under the Medicaid Drug Rebate Program, a drug manufacturer must enter into a Medicaid national drug rebate agreement with the Secretary of the U.S. Department of Health and Human Services in order for states to receive federal funding for using the manufacturer’s products. In exchange for the rebates, state Medicaid programs must generally cover all of a participating manufacturer’s drugs when prescribed for a medically accepted indication, although the states may limit the use of some drugs through preferred drug lists, prior authorization, and quantity limits. The rebates under the Medicaid Drug Rebate Program are defined in statute. States may also negotiate their own supplemental rebates with manufacturers.

The Medicaid Drug Rebate Program defines a covered outpatient drug generally as a drug that may be dispensed upon prescription and has been approved by the Food and Drug Administration for safety and effectiveness. Covered outpatient drugs do not include drugs provided and billed as part of a bundled service within certain setting such as an inpatient hospital or nursing facility stay. Physician-administered drugs may be eligible for a rebate as long as the drug meets the definition of a covered outpatient drug.

Learn more about how Medicaid pays for outpatient prescription drugs, MACPAC’s recommendations to improve the operations of the drug rebate program, and other issues.

Click here for our Medicaid 101 series on YouTube.

Featured Publications

Improving Access to Medications for Opioid Use Disorder: Themes from Stakeholder Interviews

February 27, 2025

In 2022, Medicaid and the State Children’s Health Insurance Program (CHIP) were the primary source of coverage for 38 percent of youth and non-elderly adults with opioid use disorder, representing 1.9 million beneficiaries. Given the ongoing drug-overdose crisis and Medicaid’s role in facilitating treatment, MACPAC has been engaged in research to understand access to and […]

Panel Discussion: Substance Use Disorder Section 1115 Demonstrations

February 27, 2025

Substance use disorder (SUD) is a significant public health issue that disproportionately affects the Medicaid program. Historically, Medicaid has provided limited coverage for residential SUD treatment due to federal rules prohibiting federal matching funds for services provided in institutions for mental disease (IMDs). That policy has made it difficult for states to meet the need […]

Comment Letter: Proposed Rule on Policy and Technical Changes to Medicare Advantage for Contract Year 2026

January 17, 2025

In a letter to Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure, MACPAC commented on a CMS proposed rule on technical changes to Medicare Advantage (MA) for contract year 2026.
The proposed rule would make mandatory coverage of certain weight loss drugs for obesity through Medicaid, for which states will need to develop coverage […]